Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

New Drug May Be Effective for Lung Cancer Patients with RET Mutations

New Drug May Be Effective for Lung Cancer Patients with RET Mutations | Lung Cancer Dispatch | Scoop.it

Some patients with non-small cell lung cancer (NSCLC) have tumor mutations called "RET fusions." RET fusions are especially common in patients who have adenocarcinoma, never smoked, and/or have no mutations in other genes commonly associated with NSCLC. In an ongoing phase II clinical trial, three patients with adenocarcinoma and RET fusions appeared to respond well to the drug cabozantinib (Cometriq). The tumors of two of the patients shrank during Cometriq treatment, while the third experienced stable disease. Further studies are needed, but these results suggest that Cometriq may be an effective treatment for NSCLC patients with RET fusions. Research paper: http://cancerdiscovery.aacrjournals.org/content/early/2013/03/23/2159-8290.CD-13-0035.abstract

Cancer Commons's insight:

Cancer Discovery | Mar 26, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Inhibition of MET May Help Overcome TKI Drug Resistance in Lung Cancer

Inhibition of MET May Help Overcome TKI Drug Resistance in Lung Cancer | Lung Cancer Dispatch | Scoop.it

Tyrosine kinase inhibitors (TKIs) that block EGFR are effective treatments for many cases of advanced non-small cell lung cancer (NSCLC), but are limited by the fact that patients will eventually develop resistance against them. Overexpression of the MET gene may contribute to EGFR-TKI resistance, suggesting that combined inhibition of both EGFR and MET may prevent or overcome this drug resistance. Several MET inhibitors have been developed, including cabozantinib (Cometriq), tivantinib, onartuzumab, and ficlatuzumab, and ongoing trials are investigating the safety and effectiveness of combining them with an EGFR-TKI like erlotinib (Tarceva) or gefitinib (Iressa).


Research paper: http://theoncologist.alphamedpress.org/content/early/2013/01/25/theoncologist.2012-0262.full.pdf

Cancer Commons's insight:

The Oncologist | Jan 28, 2013

more...
No comment yet.